20S proteasome 904
22Rv1 166
4EGI-1 1660
8-oxodG 344
ABCB1 1395
ABCG2 1320
abdominal cancer 490
ABL1 157
acidity 1280
acute myeloid leukaemia 475
adenoma 517
adenosine triphosphate-based chemotherapy response assay 53
adhesion 1535
Adjuvant! Online 1760
adjuvant 32
adjuvant chemotherapy 1239, 1268
advanced 1068
advanced breast cancer 440
advanced gastric cancer 1039
afatinib 6
age 1068, 1353
AIDS 447
Akt 1196
alcohol 592, 1881
ALDH1 846
ALK 1100
Amphiregulin 1406
anaemia 909
anal carcinoma and survival 756
anchorage-independent growth 553
angiogenesis 314, 896, 1089, 1153, 1495, 2004
angiotensin II-converting enzyme inhibitor 290
angiotensin II receptor blocker 290
animal exposure 966
ANPEP 157
antiangiogenesis 678
antifungal 1626
anti-HER2 therapy 673
apoptosis 314, 693, 711, 763, 839, 858, 1288, 1499, 1551, 1953
arginine 1481
arginine deiminase 324, 1481
argininosuccinate synthetase 324
aromatase inhibitor 1062, 1618
asbestos 575, 1016
aspirin 1564
ataxia telangiectasia 262
ATM 262
atrasentan 284
attitudes 1907
attributable fractions 1346
atypical endometrioid hyperplasia 1297
aurora kinase A 748, 1798
automated counting method 383
autophagy 324, 693, 711
avoidable deaths 1846
awareness 1907
AZD2281 468
β-catenin 1395
barasertib 858
Bcl-2 gene family 839
beta2-Microglobulin 1239
beta-catenin 517
bevacizumab 453, 468, 799, 1718, 1926
BH3 mimetic 711
biglycan 1214
bile duct cancer 1011
bile reflux 1342
biliary tumour 1011
BIM 763
biomarker 18, 85, 133, 148, 189, 199, 414, 460, 733, 955, 1039, 1153, 1160, 1506, 1718, 1989, 1960
bladder cancer 222, 366, 496, 1177, 1187, 1891
bone marrow stroma 1689
bortezomib 333
BRAF 939
brain metastases 25, 440, 1850
brain tumour 1702
BRCA1/2 mutation carriers 2016
BRCA1 775, 1234, 1697
BRCA1/2 780
BRCA2 775
breast/ovarian cancer risk 2016
breast cancer 6, 25, 189, 248, 262, 375, 389, 397, 525, 592, 673, 780, 826, 916, 923, 1045, 1053, 1062, 1117, 1166, 1234, 1361, 1367, 1605, 1611, 1618, 1675, 1790, 1850, 1907, 1910, 1917
breast cancer risk factors 996
breast cancer subtype 1107
breast-conserving surgery 1160
breast density 996
breast neoplasms 1560
breast tumour cells 693
bystander effect 889
CA-125 633
cachexia 1583
CA IX 916
calcifications 525
calcium 1335
cancer cell resistance 1648
cancer cell viability 116
cancer drug targets 254
Cancer Referral Guidelines 436
cancer registry 1910
cancer screening 1361
cancer stem cell 99, 1320, 1512, 1997
cancer targets 1123
cap-dependent translation 1660
CAPIRI 453
carboplatin 70, 633, 1728
carboplatin resistance 482
carcinoma 1495
carcinomatous meningitis 440
case–control study 447, 1331, 1346
caspases 1499
Cav-1 1187
CCP score 1095
CD133 1997
CD151 923
CD24 846
CD44 846
CD46 1543
CD59 1543
CD55 1543
cell cycle 693
cell cycle genes 1095
cell death 711
cell death mechanisms 1766
CellSearch 508
cellular immunotherapy 1123
cervical cancer 1520, 1526, 1753
cervical cancer screening 1571
cervical cytology 817
cervical intraepithelial neoplasia 45, 817, 975, 1753
cetuximab 274, 793, 1406
CHAC1 189
checkpoint 429
chemical genomics 254
chemical proteomics 254
chemoembolisation 1274
chemokines 1306
chemoprevention 45
chemoradiotherapy 61
chemo-response 1967
chemosensitivity 333
chemotherapy 274, 651, 658, 896, 947, 988, 1033, 1076, 1591, 1605, 1934
chemotherapy resistance 1901
childhood cancer 982
childhood infections 1331
childhood leukaemia 1556
Chlamydophila psittaci 966
cholangiocarcinoma 1583
chrysotile 575
circulating-free DNA 375
circulating tumour cells 375, 508, 939, 1605, 1790
circulating tumour microemboli 508
cisplatin 460, 658, 1027
c-Jun 1997
CK-19mRNA 1917
class predictor 126
clinical practice 1760
clonal growth 1506
clusterin 1945
CML 1742, 1772
CNS metastasis 397
CNS symptoms 839
coeliac disease 217
cohort 210, 217, 596, 1004, 1011, 1842
colon cancer 748, 1239, 1268, 1395
colon cancer cell lines 141
Colorectal 1386, 1718, 1907
colorectal adenoma 608
colorectal cancer 18, 126, 133, 141, 227, 517, 793, 799, 805, 931, 1320, 1335, 1374, 1431, 1499, 1564, 1713, 1722, 1735, 1826, 1833, 1875, 1926, 2010
colorectal cancer liver metastases 1274
colorectal cancer screening 1424
combination chemotherapy 1728
combination therapy 107, 1386, 1742, 1779
common variants 389
comorbidity 1353, 1860
competing risks 1846
complex intervention 826
confidence interval 1846
conformal radiotherapy 61
controlled clinical trials 1259
copy number 748
cost 1045
cost-effectiveness 805, 1100, 1571
C-reactive protein 702
crizotinib 1100
crocidolite 1016
CRP 1866
CXCL12 1306, 1520
CXCR2 1833
CXCR4 1306, 1520
CXCR7 1520
cyclin-dependent kinase 133
cytochrome-c 889
cytokines 1134
cytology 975
cytotoxic 1379
D310 mutation 1506
dacarbazine 85
dasatinib 85
data integration 1107
DCE-MRI 1926
DCIS 1160, 1506, 1611
decision 1045
decision aid 1053
decision-making 1053
definitions 1262
definitive RCT 826
delayed infection 1556
deletion 719
dendritic cells 546
depsipeptide 116
detection 436, 1605
diabetes 1374
diagnosis 733, 904, 909, 982, 1068, 1431, 1556, 1940
diagnostic intervals 1262
diet 603, 608, 1891
dietary fat 596
diffusion-weighted magnetic resonance imaging 1638
diindolylmethane (DIM) 45
disease-free survival 955
disease progression 1249
disseminated tumour cells 375
DMXAA 1134
DNA damage response 429
DNA methylation 248, 414, 585
DNase 206
docetaxel 858, 1469
dormancy 375
dose escalation 678, 1598
double-strand DNA repair 1460
doublet 658
doxorubicin 916
driver-network 1107
drug discovery 254
drug–drug interaction 1772
drug resistance 1089, 1901
drug sensitivity 116, 867
DSC1 756
dual erbB protein kinase inhibitor family 666
ductal carcinoma in situ 1611, 1675
duodeno-gastro-oesophageal reflux 1342
dynamic equilibrium 1512
E7080 1598
early breast cancer 1760
early detection of cancer 975
early diagnosis 1262
EBNA1 206
EBV 1980
E-cadherin 756
education of patients 651
EEF1A1 166
EEF1A2 166
effectiveness 1045
effectiveness of the QoL system 826
EGFR HER2 719
EGFR PharmDx 883
EGFRvIII 883
eIF4F complex 1660
elderly 274, 1353
electromagnetic fields 307
ELISA 1495
EML4–ALK 763
EMT 1196, 1735
endometrial cancer 1551, 1682
endometrioid endometrial cancer 1297
endothelin axis 284
enzautaurin 867
EPIC 1866
epidemiologic methods 569
epidemiologic studies 970
epidemiology 1860
epidermal growth factor receptor 666, 883, 1100, 1196, 1367, 1406, 1520
epigenetically silenced 482
epigenetics 248, 414, 1446
epinephrine 460
Epiregulin 1406
epithelial cells 1205
epithelial mesenchymal transition 1512
epothilones 70
Epstein–Barr virus 206
ERα 1682
ER positive 1798
erythropoiesis-stimulating agents 1249
erythropoietin receptor 1249
ESFT cell lines 1288
ethnicity 1361
everolimus 876, 1039
evolutionary game theory 174
Ewing's sarcoma family of tumours 1123, 1224
exemestane 1062
exon array 538
expected survival 1854
expression profiling 538, 1095
extracellular 1453
extracellular signal-regulated protein kinase (ERK) 1997
eye 1171
EZH2 243
FADD 1989
faecal immunochemical test 805
faecal occult blood tests 1424
family history 780
Fas/Fas L upregulation 1288
FBXW7 182
FDG-PET/CT 1926
fertility 1053
FFPE 538
FGFR2 727
FGFR3 1406
fine-needle aspiration biopsy 562
first-in-human 666
five subtypes 923
flexible sigmoidoscopy 805
FLT3 475
FLT3-ITD 475
fluconazole 1626
FOBT 805
FOLFIRI 453
FOLFOX therapy 126
follow-up 1611
food supplement 45
FUS-DDIT3 1976
fusogenic glycoprotein 496
gallstones 1011
gamma-glutamyltransferase 1551
gamma-glutamyltranspeptidase 1551
gastric adenocarcinoma 733
gastric cancer 210, 585, 685, 727, 740, 1469, 1535, 1591, 1668
gastric resection 1342
gastric surgery 1342
GD2 1123
gefitinib 1148, 1196
gemcitabine 1934
geminin 1798
gene amplification 727
gene-body 248
gene expression 867, 1648, 1967
gene mutations 1648
genetic testing 1234
gene transfer 1123
genomic stability 1297
genotype 1591
γH2AX 1807
Glasgow Prognostic Score 279
glioblastoma 1702
glioma 538
glucose 227
glutathione 1551
GPER 1682
GPRD 233
growth factors 1033, 2004
γ-secretase inhibitor 1953
GSK-3β 1196
HA14-1 711
haeme iron 608
HDAC-inhibitor 116, 1682
head and neck cancer 1526
head–neck cancer radiotherapy 846
health personnel 651
health services research 1021
Hedgehog signalling pathway 1177
heparanase 1486
hepatocellular carcinoma 307, 1439
hepatocellular carcinoma metastasis 1486
HER2 6, 1367, 1453
Her2neu 1543
HER2+ 25, 32
hereditability 389
hereditary 1460
histamine-2-receptor antagonists 233
histone deacetylase inhibitor 77, 107
histone methyltransferase 243
HIV 447
HLA class I 1980
HMW-MAA 939
homeostasis model assessment-insulin resistance 227
hormone receptor-positive 1760
HPV vaccination 1571
human 1224
human 8-oxoguanine DNA glycosylase 344
human epidermal growth factor receptor 2 (HER-2)-positive breast cancer 440
human papillomavirus (HPV) 45, 222, 358, 817, 975, 1526, 1753
human polyomavirus 222
hybrid capture 975
hydroxyapatite 525
hypergastrinaemia 233
Hypertension 1718
hypoxia 314, 904, 916
hypoxia hypoxia-inducible factor-1 1638
ICR10 883
IFN-α 284
IgA 206
IGF1R 1367
IGFBP-3 1004
IGF-I 1004
IHC4 1760
IL23R 517
IL-6 1866
IL-8 1833
imaging biomarker 619
Imatinib 1772
immortalisation 1205
immune-modulation 896
immunodeficiency 447
immunohistochemistry 141, 883, 947, 1033, 1926
immunotherapy 793, 896, 988
imputation 1068
incidence 962, 970, 1335, 1753, 1850
India 962
indole-3-carbinol (I3C) 45, 333
indoleamine 2,3-dioxygenase 1 141
inequalities 1361
infections 1556, 1626
inflammation 199, 217, 1439, 1866, 2010
inflammatory markers 1424
iNOS 889
in situ hybridisation 1790
insulin resistance 1335
integrin-β1 846
integrin signalling 1535
inter-conversion 1512
interferon-α 1742
interleukin-6 1583
internet 651
intolerance 1475
intragenic 248
intraperitoneal perioperative chemotherapy 460
invasion 148, 553
invasive margin 2010
in vivo 324
ionising radiation 889
irinotecan 18, 1591
irreversible electroporation 490
ISET 508
Ki67 1798
kidney cancer 1475
kinase inhibitor 475
KIT 939
κ-opioid receptor 1148
KRAS 1406, 1722, 1826
KRAS mutation 748
lapatinib 6, 25, 673
laser-induced thermotherapy 1274
LDH 799
LD radiolabelling 1027
let-7 1415
letrozole 1618
leukocyte 585
life change events 1560
Lin28 1415
Lin28B 1415
liposomal doxorubicin 1027
liver metastases 1926
liver resection 53
LMP1 1980
LNCaP 166
localised prostate cancer 1095
locally advanced 61
locally advanced cervical cancer 39
low-risk GTN 1089
lung cancer 447, 575, 867, 1100, 1153, 1346, 1854, 1907
lymphangiogenesis 348
lysate therapy 92
M30 ELISA 1766
M65 ELISA 1766
machine learning algorithm 126
magnesium 1335
magnetic resonance spectroscopy 1638
malignant melanoma 553
malignant pleural mesothelioma 1027
mammography 525
marker protein patterns 1297
mass screening 805, 970
mathematical model 1280, 1742
matrix metallopeptidase 1486
matrix metalloproteinase 1431, 1495
MCM2 1798
mCRC 453
MCV 1166
MDA-7/IL-24 1976
meat 603, 608
meat mutagens 608
MEK 1386
melanocyte 553
melanoma 85, 939, 970, 1134, 1446, 1481
melatonin 1288
menarche 210
menopause 210
mental health 1842
Merkel cell carcinoma 1166, 1314
Merkel cell polyomavirus 1314
mesenchymal stem cells 1901
mesothelioma 575, 1016
meta-analysis 603, 1881
metastasis 133, 148, 174, 348, 1446, 1535, 1668, 1689, 1718
metastatic colorectal cancer 274
metastatic renal cell carcinoma 646, 1587
metformin 1117, 1374
methodology 854
methods 1262
Microarray 1779
microcalcifications 525
micro CT 496
micrometastasis 1675
micronucleus test 780
micronutrients 1891
microRNA 182, 366, 405, 740, 1526, 1826
microRNA expression 768
microsatellite analysis (MSA) 1171
microsatellite instability 1239
microvesicles 896
microvessel 702
Mifamurtide 14
mineralisation 525
miR-143 366
miR-145 366
miR-1 and miR-133a 405
miR-328 1320
mitochondria 1224
mitochondrial DNA 1506
mitotic spindle 307
MMP16 1320
model 1045
molecular clustering 538
molecularly targeted agents 854
molecular marker 562, 909, 1177
MOLM-13 475
monosomy 3 1171
morphology 1875
mortality 1560, 1842
mRCC 284
MRI 1960
Mrna 1790
MRP-1 1224
MTHFR 677 C4T polymorphism 2016
mTOR 876, 1386
mTOR inhibitor 1475
multi-drug resistance 1224, 1395
multi-kinase inhibitor 1722
multiparametric imaging 619
multiple 1068
multiple myeloma 546, 1660
multiple risk-allele GWA replication 389
mumps 1331
mutation screening 1697
MV4-11 475
myxoid liposarcoma 1976
naevus 553
Na,K-ATPase 1807
Nanog 1702
nasopharyngeal carcinoma 206
NAV3 517
necrosis 702
needle biopsy 1095
neoadjuvant chemotherapy 53
nephrectomy 279
network analysis 1107
Neuroblastoma 1807
nitrate 608
nomogram 1083
non-Hodgkin’s lymphomas 966, 988
non-seminoma 414
non-small cell lung cancer (NSCLC) 658, 763, 1148, 1953, 1989
normal mucosa 1495
Notch 1953
novel marine-derived compound 1379
Noxa 1660
NPC 1980
NSAIDs 1564, 1772
NSC-134754 1638
NT5E 1446
nurses 651
occupational 1346
OCT-1 1772
Oct4 846
ocular adnexal marginal zone B-cell lymphoma epidemiology 966
oesophageal cancer 210, 702, 711, 955, 1342, 1415
oesophageal squamous cell carcinoma 876, 947
oestrogen receptor 1062, 1205, 1453
OGX-011 1945
olaparib 468
oncogene mutations 939
oncology trials 854
oncolytic HSV 496
one-step nucleic acid amplification assay 1675
oophorectomy 775
orchitis 1331
oropharynx 358
orphan drugs 14
orthotopic model 348, 496
Ouabain 1807
ovarian cancer 70, 189, 333, 482, 596, 629, 633, 1306, 1460, 1779, 1860, 1967
ovarian endometrioma 1205
overall survival 1374
OXi4503 1766
oxidative stress 99, 344
P16 358
P2037 metastasis 1535
p53 397
p57Kip2 482
paclitaxel 633, 1728
PAI-1 366
pancreatic cancer 61, 233, 348, 508, 603, 1004, 1033, 1866, 1934, 1940
paraaortic lymphadenectomy 39
parity 210
PARP inhibitors 18, 1460
partial monosomy 3 1171
pazopanib 629
PC-3 166
pegylated liposomal doxorubicin 633
pelvic lymphadenectomy 39
period analysis 1875
peritumoural 2010
personalised therapy 126
pertuzumab 1779
PFTK1 947
Pharmacokinetics 1598
pharmacokinetics 678
phase 1 468, 619, 629, 673, 1379, 1598, 1766
Phase II 453, 1027
phase III 1268
phase I TAK-285 666
PHB 1630 C4T polymorphism 2016
phenformin 1117
phosphoinositol 3 kinase inhibitor 107
physicians 651
PI3 kinase 1386, 1535
PKA 1648
PKC inhibitor 867
plasma 740, 768
plasma C-peptide 1335
platinum agents 1967
PLP2 307
PM00104 1379
Polycomb proteins 243
population-based 1011, 1564
population mixing 1556
population pharmacokinetics 460
positive predictive values 1940
PPARγ 1486
PPARγ agonist 1702
prediction, biological marker 947
predictions 1016
predictive factors 799
preferences 638
primary care 1940
primary healthcare 982
primary invasive breast cancer 383
prodrug therapy 496
progestin 1205
prognosis 133, 189, 297, 719, 904, 909, 923, 931, 1076, 1083, 1171, 1439, 1499, 1551, 1560, 1713, 1798, 1826, 1989
prognostic 1760
prognostic biomarkers 2004
prognostic factors 1095, 1177
prognostic index 1439
prognostic marker 1239
prognostic tool 646
progression-free survival 1587
proliferation 876
prophylaxis 1626
prospective studies 603
prostate cancer 99, 157, 166, 174, 217, 405, 436, 638, 768, 909, 1166, 1689, 1697
protein target identification 254
proteomics 955
proton pump inhibitors 233
PSCA 157
psychological stress 1560
PTEN/PI3K/Akt pathway 1367
PTEN 719
purine nucleoside phosphorylase (PNP) 405
qPCR 157, 1605
Q-TWiST 1587
quality-adjusted survival 1587
quality of life (QoL) 638, 646, 826, 1062, 1618, 1027
quiescence 1807
RAD001 876, 1475
RAD51C 1460
RAD51D 1460
radiation 297, 1512, 1953
radiation-induced 297
radiological 633
radiosensitivity 262
radiotherapy 262, 988
random error 1846
randomised, controlled trial 45, 1934
reactive oxygen species 314, 344
receptor tyrosine kinase inhibitor 666, 1598
RECIST 854
recurrence 1160, 1560
recurrence-free survival 2004
regional lymph node metastasis 1735
regional variation 1846
registries 569
Regorafenib 1722
regulatory strategy 14
regulatory T cells 546
relative survival 1846, 1854
release 1989
renal cancer 279, 904
renal cell cancer 1881
renal cell carcinoma 1945
renal pelvis: ureter 1083
renin-angiotensin system 290
response assessment 854
response rates 1021
retinoic acid receptor 77
retrospective review 1374
review 603
RhoGD12 1187
rIL-21 793
risk 1431, 1697
risk modification 996
risk prediction 199
risk profiles 436
RO 5323441 678
ROS 889
RT–PCR 1177, 1314
S-1 1268, 1934
sagopilone 70
salinomycin 99
salivary gland cancer 719
salvage therapy 1591
sample size 1259
saracatinib 1728
sarcoma 297
SATB2 931
second-line chemotherapy 1469
scheduling 858
scoring system 1713
screening 733, 817, 1431, 1753
secondary malignancies 297
self-reporting 1910
seliciclib 482
Selumetinib 858, 1648
seminoma 414
sensitivity analysis 1854
sentinel lymph node 1314, 1675
sentinel node biopsy 39, 1045
serum 768, 1431
serum insulin 227
sexually transmitted disease 1753
side population cells 1320
sigma-2 receptors 693
signal regulated kinase 1453
signet ring cell carcinoma 1668
Sikkim 962
skeletal muscle 1583
skin neoplasms 970
small cell lung cancer 324, 839
small-molecule library screening 254
smoking 447, 1854
snail 1196
SNP 1495
socioeconomic position 988
socioeconomic status 1556
sodium bicarbonate 1280
soft tissue sarcoma 1076
solid tumours 77, 1598
somatic evolution 174
sorafenib 1945
Sox2 1702
sphingosine-1-phosphate 909, 1453
sphingosine 1-phosphate receptor 4 1453
sphingosine kinase 1453
squamous cancer 358
squamous cell carcinoma 107
Src 85, 1728, 1960
Src kinase 1187
stage 1068
statins 685, 1689
stem cells 1702
stemness genes 1702
stratification 1259
stroma 1134, 2004
subjective cognitive function 1618
subsite 1875
sunitinib 646, 1469, 1587
surveys 1021
survival 39, 383, 569, 592, 646, 702, 955, 988, 1083, 1187, 1353, 1439, 1495, 1520, 1564, 1842, 1875, 1907, 2010
survival benefit 638
survivin 763
SVM 1735
symptoms 1940
synergy 333
systematic review 780
systemic inflammatory response 279, 2010
tamoxifen 1618
Taqman 157
targeted agents 619
targeted therapy 148, 1826
taxanes 685, 1967
TB-403 678
T-DM1 6
TDP1 18
temozolomide 858
testicular cancer 414
testicular germ cell tumours 1331
tetraspanin 923
thalidomide 1153
therapy 174, 1117
therapy response 1395
thioredoxin 314
thyroid tumours 562
tissue inhibitors of metalloproteinase 1486
tissue recovery 490
TLS–CHOP 1976
TNF receptor 1866
TNM stage 1713
tolerability 678
tonsillar cancer 1526
topoisomerase I 18
TP53 348
trade-off 638
trastuzumab 6, 25, 32, 1543, 1779
trastuzumab resistance 1367
treatment prediction 931
treatment-related morbidity 297
treatment response 53
triage 817
trichostatin A 116
TRIP13 157
triple-negative breast cancer 397, 1107, 1234
triple-negative disease 440
triplet 658
tumour angiogenesis 1214, 1722
tumour biopsy 508
tumour budding 1713
tumour cells 1917
tumour endothelial cells 1214
tumour growth kinetics 854
tumour immunotherapy 92
tumour inflammatory infiltrate 702
tumour invasion front 141
tumour microenvironment 1833
tumour progression 1901
tumour staging 279, 1314
tumour-supernatants 896
tumour suppressor 405
tumour virus 429
TWiST 1587
UAPI 1089
ubiquitin ligase 182
UDP-glucuronosyltransferase 1591
UFT 1268
UKCTOCS 1910
unresectable 61
unresectable colorectal liver metastasis 53
upper-tract urothelial carcinoma 290
uptake 775
urine 768
urothelial carcinoma 1083
uterine serous cancer 1543
utility 638
uveal melanoma 1171
value-based pricing 14
vascular disrupting agent 1766
VCA 206
VEGF 284, 1960
VEGF-targeted therapy 1475
vinorelbine 673
visual counting method 383
VLP 92
vulvar brush 269
vulvar cytology 269
vulvar dysplasia 269
vulvar intraepithelial neoplasia 269
web-based 1076
Weibull model 646
Wittenoom 1016
XCL2 307
xenografts 1117, 1134
xenograft tumours 333
XMRV 1166
young women 1053
Change history
23 January 2013
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Keyword Index for Volume 106. Br J Cancer 106, 2035–2038 (2012). https://doi.org/10.1038/bjc.2012.248
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2012.248